Orchestra BioMed (OBIO) & Its Rivals Financial Review

Orchestra BioMed (NASDAQ:OBIO) is one of 228 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its competitors? We will compare Orchestra BioMed to similar companies based on the strength of its risk, dividends, earnings, valuation, analyst recommendations, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Orchestra BioMed and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	0	0	2	0	3.00
Orchestra BioMed Competitors	1527	3805	7786	210	2.50

Orchestra BioMed currently has a consensus price target of $17.00, indicating a potential upside of 276.11%. As a group, “Surgical & medical instruments” companies have a potential upside of 32.54%. Given Orchestra BioMed’s stronger consensus rating and higher possible upside, research analysts plainly believe Orchestra BioMed is more favorable than its competitors.

Volatility and Risk

Orchestra BioMed has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, Orchestra BioMed’s competitors have a beta of 1.12, meaning that their average share price is 12% more volatile than the S&P 500.

Insider & Institutional Ownership

53.6% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.6% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Orchestra BioMed and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-1,779.71%	-58.32%	-41.47%
Orchestra BioMed Competitors	-760.47%	-151.75%	-30.24%

Earnings & Valuation

This table compares Orchestra BioMed and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Orchestra BioMed	$2.76 million	-$49.12 million	-3.01
Orchestra BioMed Competitors	$817.87 million	-$23.67 million	-7.95

Orchestra BioMed’s competitors have higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Orchestra BioMed competitors beat Orchestra BioMed on 7 of the 13 factors compared.

Orchestra BioMed Company Profile

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.